Literature DB >> 16399021

Gonadal steroids in critical illness.

Jeffrey I Mechanick1, David M Nierman.   

Abstract

Gonadal steroids are metabolized in target cells and then interact with specific receptors to exert genomic and nongenomic effects. Complex feedback loops that involve the immune-neuroendocrine axis, limbic system, and gonadal steroids play a vital role in the adaptation to critical illness. Preclinical studies demonstrate adverse physiological effects of androgens on the cardiovascular and immune systems despite its purported anabolic effects. Similar models also demonstrate salutary effects of estrogens on these systems. Thus, during the catabolic phases of acute and chronic critical illness, estrogen, and not androgen, therapy may prove to be a valuable intervention. However, during the post-critical illness recovery phase, when anabolism is critical, androgen therapy may still be useful and safe.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16399021     DOI: 10.1016/j.ccc.2005.08.005

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  3 in total

Review 1.  Chronic critical illness: are we saving patients or creating victims?

Authors:  Sergio Henrique Loss; Diego Silva Leite Nunes; Oellen Stuani Franzosi; Gabriela Soranço Salazar; Cassiano Teixeira; Silvia Regina Rios Vieira
Journal:  Rev Bras Ter Intensiva       Date:  2017 Jan-Mar

Review 2.  Sepsis as a Pan-Endocrine Illness-Endocrine Disorders in Septic Patients.

Authors:  Weronika Wasyluk; Martyna Wasyluk; Agnieszka Zwolak
Journal:  J Clin Med       Date:  2021-05-12       Impact factor: 4.241

3.  A Screening Tool to Detect Chronic Critically Ill Cardiac Surgery Patients at Risk for Low Levels of Testosterone and Somatomedin C: A Prospective Observational Pilot Study.

Authors:  Ceressa T Ward; David W Boorman; Ava Afshar; Amit Prabhakar; Babar Fiza; Laura R Pyronneau; Amber Kimathi; Carmen Paul; Berthold Moser; Vanessa Moll
Journal:  Cureus       Date:  2021-05-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.